Products - Structural heart defects | Topic | NICE

Showing 4 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 June 2024
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy [ID6470]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC